ScholarIQanswers from OpenAlex
Vertex Pharmaceuticals
FunderResearch funding and supported work
Vertex Pharmaceuticals is a funder indexed in ScholarIQ from OpenAlex.
What is known about Vertex Pharmaceuticals?
ScholarIQrecord summary
American pharmaceutical company
How many works does Vertex Pharmaceuticals have?
ScholarIQindexed works
Vertex Pharmaceuticals has 1,771 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Vertex Pharmaceuticals?
ScholarIQopenalex
The OpenAlex for Vertex Pharmaceuticals is on the source record.
What is the ROR of Vertex Pharmaceuticals?
ScholarIQror
The ROR for Vertex Pharmaceuticals is on the source record.
What are the most-cited papers on Vertex Pharmaceuticals?
ScholarIQmost cited works
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, Godela Brosnahan, Melissa A. Cadnapaphornchai, Arlene B. Chapman, Émilie Cornec-Le Gall, Joost P.H. Drenth, Ron T. Gansevoort, Peter C. Harris, Tess Harris, Shigeo Horie, Max C. Liebau, Michele Liew, Andrew Mallett, Changlin Mei, Djalila Mekahli, Dwight Odland, Albert Ong, Luiz F. Onuchic, York Pei, Ronald D. Perrone, Gopala K. Rangan, Brian Rayner, Roser Torrá, Ethan M. Balk, Craig E. Gordon, Amy Earley, Reem A. Mustafa, Olivier Devuyst
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
Raghunandan Konda, Arun Rajasekaran, Dana V. Rizk